End-in-Mind Trial Design

Plan for success with
end-in-mind clinical trial design

End-in-Mind Trial Design

Plan for success with
end-in-mind clinical trial design

End-in-Mind Trial Design - HEADER - Mobile
left_img_pattern
The right strategy today shapes the approvals of tomorrow

The right strategy today shapes the approvals
of tomorrow

Every clinical trial is more than just a study—it’s a carefully mapped journey toward regulatory approval and market success. At Rho, we believe in designing trials with the end in mind, ensuring that every step—from protocol development to final submission—aligns with your long-term goals. By integrating regulatory foresight, statistical expertise, and strategic execution from the start, we help you avoid roadblocks and accelerate the path to approval.

why_rho_img

Why Rho?

Why Rho?

Regulatory-first mindset
We align trial design with agency expectations to prevent costly delays down the road.
Seamless integration
Our experts in clinical, regulatory, and statistical strategy collaborate from day one.
Data-driven decision-making
Thoughtful planning ensures your study generates the evidence needed for approval.
End-to-end expertise
From Phase I through marketing applications, we optimize trial design at every stage.

Ready to plan smarter from the start?
Let’s design a trial that leads to success—
not setbacks.

Footer_CTA_Plan1
Scroll to Top
Laura-Helms-min

Laura Helms Reece, DrPH

From analyzing data as a Biostatistician to guiding global strategy, Dr. Helms Reece has served in many roles at Rho. Nowadays, she leads the organization with the same curiosity and heart as her parents when they launched the company, steering the transformation to make us a global CRO—without losing what makes Rho special. Dr. Helms Reece continues to work deep in the trenches, as great science and leadership are hands-on projects.

Peter Schmidt, Ph.D.

Dr. Schmidt is President and Chief Scientific Officer and provides strategic and scientific leadership across the organization. A neuroscientist by training with degrees from Harvard and Cornell, he has been a catalyst in many contexts: inventor, principal investigator, statistician, and leader. With decades of experience in biomedical research—from Parkinson’s disease to cystic fibrosis to Huntington’s—he brings the insight and expertise to further strengthen Rho’s reputation as a trusted research partner with the know-how to solve complex problems. While Dr. Schimdt maintains that clinical research is a serious business, he believes working with your CRO shouldn’t feel like it.  

Andrew_Feigin-min

Andrew Feigin, MD

Dr. Feigin is Chief Medical Officer and a leading neurologist who brings 30 years of scientific excellence to Rho. A pioneer in clinical research, he’s led over 30 trials as site principal investigator and established renowned clinical trial programs for Parkinson’s, Huntington’s, Tourette syndrome, and other movement disorders. At Rho, he brings sharp insight and strategic savvy to the trials our team supports to maintain safety, integrity, and scientific rigor. Dr. Feigin is passionate about collaboration and innovation and sees Rho as the partner with the special combination of brainpower, quality, and teamwork to make an impact where it matters most.